A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy
Results of the P.R.I.N.C.E. study
Melissa A. Stevens, MDa,
Peter A. McCullough, MD, MPHa*,1,
Kenneth J. Tobin, DOa,
John P. Speck, MDa,
Douglas C. Westveer, MD, FACCa,
Debra A. Guido-Allen, BSNa,
Gerald C. Timmis, MD, FACCa and
William W. ONeill, MD, FACCa
a William Beaumont Hospital, Royal Oak, Michigan, USA
* Henry Ford Health System, Detroit, Michigan, USA

View larger version (19K):
[in a new window]
|
Figure 1 Mean individual change in serum creatinine at 48 h in the control group and the two subsets of the experimental group. IVF = intravenous 0.45 normal saline at 150 ml/h for 6 h with upward adjustment for urine flow rates greater than 150 ml/h (control group). F = furosemide 1 mg/kg intravenously up to 100 mg at the start of the procedure. D = intravenous dopamine 3 mcg/kg/min at the start of the procedure and continued for 6 h. M = mannitol 12.5 g in 250 ml of 5% dextrose infused at the start of the procedure over a 2-h period. p = 0.21 by analysis of variance.
|
|

View larger version (30K):
[in a new window]
|
Figure 2 Change in postcontrast exposure serum creatinine at 48 h stratified by measured urine flow rate, n = 98 (to convert from mg/dl to µmol/liter, multiply by 88.4). p < 0.05 for comparison of 1st to 5th quintile.
|
|

View larger version (23K):
[in a new window]
|
Figure 4 Regression of induced urine flow rate predicting resultant change in serum creatinine from baseline to that measured at 48 h in mg/dl, controlling for baseline renal function (to convert from mg/dl to µmol/liter, multiply by 88.4). This shows a relation between increasing urine flow rates in the first 24 h after contrast exposure and reduction in renal injury measured at 48 h that is independent of baseline renal function in all 98 aggregated participants, r = 0.36; F = 5.73; p = 0.005. Urine flow rate (ml/h), beta = 0.36; t = 3.33; p = 0.001. Baseline CrCl (ml/min), beta = 0.10; t = 0.93; p = 0.36.
|
|
|